224 related articles for article (PubMed ID: 35640001)
1. A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan.
Kaneko Y; Sakurai M; Snijder R; Kokubo S; Kato D
Mod Rheumatol; 2023 Apr; 33(3):448-459. PubMed ID: 35640001
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.
Sakai R; Tanaka E; Inoue E; Harigai M
RMD Open; 2024 Jun; 10(2):. PubMed ID: 38886005
[TBL] [Abstract][Full Text] [Related]
3. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Okita Y; Etani Y; Hirao M; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Kotani T; Shiba H; Katayama M; Yamamoto K; Kumanogoh A; Okada S; Nakata K
Mod Rheumatol; 2023 Jul; 33(4):690-699. PubMed ID: 35962543
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
[TBL] [Abstract][Full Text] [Related]
5. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
[TBL] [Abstract][Full Text] [Related]
6. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.
Fang YF; Liu JR; Chang SH; Kuo CF; See LC
Int J Rheum Dis; 2022 Nov; 25(11):1254-1262. PubMed ID: 35923107
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
9. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
10. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
11. Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
Mori S; Ueki Y; Ishiwada N
Mod Rheumatol; 2023 Mar; 33(2):312-317. PubMed ID: 35348759
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
13. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Finckh A; Dehler S; Gabay C;
Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
[TBL] [Abstract][Full Text] [Related]
17. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
19. Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis.
Chen YW; Chen HH; Huang WN; Chen JP; Chen YH; Chen YM
Clin Rheumatol; 2024 Jan; 43(1):117-128. PubMed ID: 37658935
[TBL] [Abstract][Full Text] [Related]
20. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Aletaha D; Smolen JS
Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
